Dow Jones

40 807,18

1,48%

DAX

Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:ALTH

<< Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
11/01/2011	14h00	Business Wire	Allos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business Priorities	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/01/2011	22h56	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/12/2010	22h36	Edgar (US Regulatory)	Current report filing (8-K)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/12/2010	14h00	Business Wire	Allos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
20/12/2010	14h00	Business Wire	Allos Therapeutics Invites Investors to Listen to Webcast of Presentation at J.P. Morgan Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/12/2010	21h15	Business Wire	New Analysis from Phase 2b Study Reinforces Favorable Survival Data Observed with FOLOTYN® Relative to Erlotinib in Advanced...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/12/2010	15h00	Business Wire	Updated Results from FOLOTYN® Phase 1 Dose Finding Study Demonstrates Activity in Relapsed or Refractory Cutaneous T-Cell Ly...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/12/2010	15h00	Business Wire	New Analysis from FOLOTYN® PROPEL Trial Demonstrates Activity in Relapsed or Refractory Transformed Mycosis Fungoides	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/12/2010	15h00	Business Wire	Allos Therapeutics Reports New Analyses of FOLOTYN® Data from PROPEL trial in Relapsed or Refractory Peripheral T-Cell Lymphoma	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/12/2010	14h00	Business Wire	Allos Therapeutics Announces FOLOTYN® Data to Be Presented as a Late Breaker at the 2010 Chicago Multidisciplinary Symposium...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/11/2010	14h00	Business Wire	New FOLOTYN® Data to Be Presented at the 2010 American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	21h10	Edgar (US Regulatory)	Quarterly Report (10-Q)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/11/2010	21h00	Business Wire	Allos Therapeutics Reports Third Quarter 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
26/10/2010	22h00	Business Wire	Allos Therapeutics to Report Third Quarter 2010 Financial Results on November 4, 2010	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/10/2010	16h06	Dow Jones News	Allos Granted Orphan Status In Europe For Lymphoma Drug	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/10/2010	15h00	Business Wire	Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Hodgkin Lymphoma by the Eu...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2010	14h19	Dow Jones News	Allos' Pralatrexate Outperforms Tarceva In Lung-Cancer Study	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2010	13h15	Business Wire	Allos Therapeutics Announces Presentation of Favorable Survival Data from Randomized Phase 2b Study of FOLOTYN® in Patients ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/10/2010	16h00	GlobeNewswire Inc.	Allos Therapeutics, Inc. (ALTH) to Ring The NASDAQ Stock Market Closing Bell	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/09/2010	22h14	Edgar (US Regulatory)	Amended Current report filing (8-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
15/09/2010	23h40	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (3/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/09/2010	15h00	Business Wire	Allos Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/09/2010	19h29	Business Wire	Allos Therapeutics Announces FOLOTYN® Data Presentation at the 35th ESMO Congress	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/09/2010	23h50	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/09/2010	22h19	Edgar (US Regulatory)	Amended Annual Report (10-K/A)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
30/07/2010	22h17	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (S-8)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/07/2010	13h30	Business Wire	Allos Therapeutics Reports Second Quarter 2010 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
28/07/2010	13h00	Business Wire	Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/07/2010	15h00	Business Wire	Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/06/2010	15h00	Business Wire	Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ...	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)